Promega Madison Achieves ISO 14001 Certification for Environmental Management
6.5.2025 13:00:00 CEST | Business Wire | Press release
ISO 14001 is an internationally recognized standard for environmental management systems.Certification recognizes the biotechnology manufacturer’s ongoing commitment to environmental stewardship and sustainability.Promega announces certification in 2025 Corporate Responsibility Report released today
Promega Corporation announced today that its headquarters in Madison, Wisconsin has achieved ISO 14001:2015 certification, an internationally recognized standard for environmental management systems. This certification reflects the biotechnology manufacturer’s longstanding commitment to environmental stewardship and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505641030/en/
Promega Madison has achieved ISO 14001:2015 certification for its environmental management system. Promega announced the certification in its annual Corporate Responsibility Report, which also features sustainability metrics and details on how the biotechnology manufacturer supports scientists, employees and communities.
“For more than 45 years, Promega has been dedicated to environmental management and sustainable practices within the life sciences industry,” says Jaime Dwight, Director, Environmental Health & Safety and Controlled Substances. “This certification embodies the effort we have invested in fostering a culture of environmental responsibility, ensuring environmental compliance and promoting continual improvement across our operations.”
Promega announced the certification in its 2025 Corporate Responsibility Report, published today on the company’s website. In addition to sustainability metrics, the report captures how Promega supports scientists, employees and communities.
ISO 14001:2015 Certification
ISO 14001:2015 is an internationally recognized standard for environmental management systems. It provides a framework for organizations to identify, manage, monitor and improve their environmental performance. The standard helps businesses reduce waste, comply with regulations and minimize their environmental impact while enhancing sustainability efforts.
To achieve this certification, Promega demonstrated a strong environmental management system including adherence to environmental compliance requirements, mitigating environmental impact of our operations, and leadership commitment to sustainable best practices. A thorough review by independent auditors confirmed the company’s efforts in these areas.
Examples of Promega environmental initiatives include:
- Innovative product design that incorporates green chemistry and ambient shipping stability
- A global commitment to sourcing 100% renewable electricity by the end of 2025
- Employee-driven programs such as plastic film collection and recycling
- On-site composting to support the company garden using food and landscaping waste
2025 Corporate Responsibility Report
Since 2008, Promega has issued an annual Corporate Responsibility Report detailing its progress in sustainability, product impact, employee well-being and community engagement. Highlights of this year’s report include:
- Supporting Young Scientists: The Promega Rising Researchers Scientific Innovation Awards honor exceptional PhD students around the world with resources, mentorship and a visit to Promega Madison.
- Giving Back to Communities: The Promega in Action initiative gives Madison-based employees the opportunity to receive up to 40 hours of paid time off to volunteer for a nonprofit organization of their choice.
- Investing in Research and Innovation: Promega invested 13.8% of its revenue in R&D in 2024, propelling advancements in drug discovery, bioluminescence imaging and cellular metabolism.
The 2025 Corporate Responsibility Report contains additional information on how Promega considers the United Nations Sustainable Development Goals (SDGs) in its practices and actions.
Read the latest Corporate Responsibility Report here.
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250505641030/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release
Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom